The heterogeneous field of calcium and parathormone (PTH) represents a dynamic topic in terms of physiological and pathological aspects. Calcium is fundamental in the regulation of muscle and bone crosstalk both for daily activities like physical exercise or for age-related conditions such as osteoporosis. As parathormone controls calcium homeostasis, its concentration is critical for the regulation of bone remodelling. Hypoparathyroidism can cause hypocalcemia and hyperphosphatemia, while hyperparathyroidism can, instead, cause hypercalcemia and hypophosphatemia.
Parathyroid hormone administration has been officially recognized as a treatment of severe hypoparathyroidism or abaloparatide. Nevertheless, some clinicians experience challenges while using osteoanabolic medication with teriparatide in cases of severe osteoporosis, due to the varied protocols between countries.
According to the literature, asymptomatic hyperparathyroidism has been the most common clinical phenotype in the last 40 years. Updated surgical approaches for primary hyperparathyroidism-related parathyroid adenoma are showing high therapeutic efficacy. Furthermore, the introduction of a trabecular bone score provides a complementary modern tool to address the fracture risk in patients with PHP.
Late and more severe manifestations of hyperparathyroidism, such as osteitis fibrosis cystic and brown tumors, are areas that still need to be fully addressed. The genetic assessment of hypothyroidism and the identification of a potential parathyroid carcinoma are also to be improved.
The aim of this article collection is to provide an update on the clinical presentation and new therapies for parathormone imbalance.
We welcome original studies, case reports, and reviews/meta-analysis of the literature regarding, but not limited to, the following themes:
- Primary hyperparathyroidism (PHP) with atypical presentation, management of asymptomatic cases, unusual complications such as osteitis fibrosis cystic, brown tumors, etc.
- The use of PTH (Parathyroid Hormone) – and PTHrP (Parathyroid Hormone related peptide) - related molecules as a treatment for severe osteoporosis, chronic severe hypoparathyroidism
- Pitfalls of parathyroidectomy
- Clinical approaches for genetic PHP
The heterogeneous field of calcium and parathormone (PTH) represents a dynamic topic in terms of physiological and pathological aspects. Calcium is fundamental in the regulation of muscle and bone crosstalk both for daily activities like physical exercise or for age-related conditions such as osteoporosis. As parathormone controls calcium homeostasis, its concentration is critical for the regulation of bone remodelling. Hypoparathyroidism can cause hypocalcemia and hyperphosphatemia, while hyperparathyroidism can, instead, cause hypercalcemia and hypophosphatemia.
Parathyroid hormone administration has been officially recognized as a treatment of severe hypoparathyroidism or abaloparatide. Nevertheless, some clinicians experience challenges while using osteoanabolic medication with teriparatide in cases of severe osteoporosis, due to the varied protocols between countries.
According to the literature, asymptomatic hyperparathyroidism has been the most common clinical phenotype in the last 40 years. Updated surgical approaches for primary hyperparathyroidism-related parathyroid adenoma are showing high therapeutic efficacy. Furthermore, the introduction of a trabecular bone score provides a complementary modern tool to address the fracture risk in patients with PHP.
Late and more severe manifestations of hyperparathyroidism, such as osteitis fibrosis cystic and brown tumors, are areas that still need to be fully addressed. The genetic assessment of hypothyroidism and the identification of a potential parathyroid carcinoma are also to be improved.
The aim of this article collection is to provide an update on the clinical presentation and new therapies for parathormone imbalance.
We welcome original studies, case reports, and reviews/meta-analysis of the literature regarding, but not limited to, the following themes:
- Primary hyperparathyroidism (PHP) with atypical presentation, management of asymptomatic cases, unusual complications such as osteitis fibrosis cystic, brown tumors, etc.
- The use of PTH (Parathyroid Hormone) – and PTHrP (Parathyroid Hormone related peptide) - related molecules as a treatment for severe osteoporosis, chronic severe hypoparathyroidism
- Pitfalls of parathyroidectomy
- Clinical approaches for genetic PHP
